Subscribe
sergey-nivens-shutterstock-com-1
Sergey Nivens / Shutterstock.com
26 October 2015Americas

Vertex and CRISPR Therapeutics announce research partnership

US-based Vertex Pharmaceuticals and CRISPR Therapeutics have agreed a research collaboration to discover and develop new treatments for genetic causes of human diseases.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
FDA lifts hold on first human CRISPR trial
17 October 2018   The US Food and Drug Administration has allowed the first US-based human trial of CRISPR, the gene-editing technology, to proceed.
Americas
CRISPR Therapeutics expands MaxCyte partnership into immuno-oncology
13 November 2018   Gene-editing company CRISPR Therapeutics has expanded its partnership with US-based MaxCyte, which focuses on cell-based medicines, into the immuno-oncology arena.
Biotechnology
Vertex signs $100m CRISPR deal to use sickle cell treatment
14 December 2023   Biotech firm agrees licence deal days after its gene editing treatment gets landmark FDA approval | Patents owned by the Broad Institute protect technology sold via Editas Medicines.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

More on this story

Americas
FDA lifts hold on first human CRISPR trial
17 October 2018   The US Food and Drug Administration has allowed the first US-based human trial of CRISPR, the gene-editing technology, to proceed.
Americas
CRISPR Therapeutics expands MaxCyte partnership into immuno-oncology
13 November 2018   Gene-editing company CRISPR Therapeutics has expanded its partnership with US-based MaxCyte, which focuses on cell-based medicines, into the immuno-oncology arena.
Biotechnology
Vertex signs $100m CRISPR deal to use sickle cell treatment
14 December 2023   Biotech firm agrees licence deal days after its gene editing treatment gets landmark FDA approval | Patents owned by the Broad Institute protect technology sold via Editas Medicines.

More on this story

Americas
FDA lifts hold on first human CRISPR trial
17 October 2018   The US Food and Drug Administration has allowed the first US-based human trial of CRISPR, the gene-editing technology, to proceed.
Americas
CRISPR Therapeutics expands MaxCyte partnership into immuno-oncology
13 November 2018   Gene-editing company CRISPR Therapeutics has expanded its partnership with US-based MaxCyte, which focuses on cell-based medicines, into the immuno-oncology arena.
Biotechnology
Vertex signs $100m CRISPR deal to use sickle cell treatment
14 December 2023   Biotech firm agrees licence deal days after its gene editing treatment gets landmark FDA approval | Patents owned by the Broad Institute protect technology sold via Editas Medicines.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York